Page 5 - Kaplan Meier News Today

Trial met its primary endpoint, with 64.3% of patients receiving etripamil converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR =...

Biophytis / Key word(s): Study resultsBiophytis reports positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in COVID-19 03-Nov-2022 / 08:00 CET/CEST Biophytis reports positive post-hoc analysis of the phase 2-3 COVA clinical study stron...

─ Trial met its primary endpoint, with 64.3% of patients self-administering etripamil converting to sinus rhythm within 30 minutes compared to 31.2% on placebo...

/PRNewswire/ -- CorePlus Servicios Clínicos y Patológicos, LLC (CorePlus), a leader in AI-based solutions for cancer detection in pathology, is scaling their...

LEWISVILLE, Texas--(BUSINESS WIRE)--Oct 10, 2022--

Although it is known that prosthesis-patient mismatch causes worse outcomes in surgical aortic valve replacement, a new meta-analysis shows this is also the case in transcatheter procedures.

The study is the first to explore gender differences in detail in pediatric and adolescent patients with melanoma, according to one of the investigators.

Data Show INT230-6 is Well Tolerated and Elicits Both Direct Tumor Killing and Immune Activating Effects in a Variety of Sarcomas In a Heavily Pre-Treated,...

New subgroup analyses presented at Digestive Disease Week (DDW) 2022 on the integrated efficacy results of Phase 2b and Phase 3 clinical studies of RBX2660. Data adds to the growing body

The FDA has approved Olumiant (baricitinib) for the treatment of COVID-19 in certain hospitalized adults.